August 11, 2023 02:58 PM EDTUpdated August 12, 01:49 PM
Pharma
FDA+

No­vo Nordisk buck­les down on lob­by­ing ef­forts, inch­ing to­ward CMS cov­er­age of obe­si­ty treat­ments

Lia DeGroot

No­vo Nordisk has spent the sum­mer build­ing out its lob­by­ing team on K Street as part of its ef­forts to get Medicare to cov­er obe­si­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

A service from the Financial Times